The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.
Real-world study results suggest that people with type 2 diabetes treated with insulin monotherapy have worse clinical outcomes than those given combination treatment with insulin and other antidiabetic drugs.
Older individuals with type 2 diabetes have a high risk for frailty, and risk predictors include poor glycemic control, depressive symptoms, and lifestyle factors, suggest findings from a Chinese cross-sectional study.
People with type 2 diabetes, particularly those diagnosed at a young age, can face an extended wait for medication to treat cardiovascular risk factors, even if they are in a high-risk category, research shows.
Integrating a comprehensive management plan into the World Health Organization maternal care framework has the potential to improve pregnancy outcomes for women with type 1 diabetes, suggest findings from the CARNATION study.
Single-step screening for gestational diabetes makes twice the number of diagnoses of the two-step approach without resulting in better outcomes for women and infants, shows the randomized ScreenR2GDM trial.
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Older individuals with type 2 diabetes and low glycated hemoglobin receiving treatment with a sulfonylurea or insulin have an increased risk for severe hypoglycemia, but there is no clear indication of an increased mortality risk, suggest UK study results.
Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.